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This study aimed to synthesize available evidence on the analgesic efficacy of buprenorphine in treating cancer
pain and related adverse effects. We searched electronic databases for randomized controlled trials, assessing the
efficacy of buprenorphine, regardless of delivery system. The primary endpoints were patient-reported ‘pain intensity’
and ‘pain relief’. Statistical heterogeneity among included studies was assessed with the I2 test. The summary relative
risk (RR) and 95% CI were derived, if two or more studies reported the similar outcome. Sixteen RCTs (n = 1329) with
buprenorphine were included: 8 transdermal (TD), 5 sublingual (SL), 2 intramuscular injection (IM) and 1 subcutaneous
infusion (SC) studies; with both SL and IM routes being assessed in one study. Only a few studies reported the same
outcome in a similar way, creating difficulty for pooling of the outcome data. Many studies had a high risk of bias. In 2
studies (n = 241), the ‘global impression change’ was significantly different between TD buprenorphine and the
combined placebo and morphine (RR 1.35, 95% CI 1.14-1.59; I2: 42%); the ‘number-needed-to-treat’ (NNT) was 4.9
(95% CI: 3.1-10.9). In 2 studies (n = 331), ‘requirement for rescue SL buprenorphine’ was comparable between TD
buprenorphine and placebo (RR 1.25, 95% CI 0.71-2.18; I2 : 40%). In 2 studies (n = 141), ‘incidence of nausea’ was less in
TD buprenorphine (RR: 0.38, 95% CI: 0.2-0.71, I2: 0%, NNT: 9.3, 5.6-28.5). Due to the small number of participants in a
small number of studies, the results of the present review provide insufficient evidence to position adequately the use
of buprenorphine in treatment of cancer pain. Large multicenter RCTs that compare TD buprenorphine with standard
analgesic treatment is needed to position TD buprenorphine in the therapeutic armamentarium of cancer pain treatment.
Keywords: Buprenorphine; Efficacy; Randomized controlled trials; Meta-analysisIntroduction
Worldwide cancer is one of the leading causes of morbid-
ity and mortality. In 2012 new cases of cancer was esti-
mated to be 14.1 million per year (ICRC 2012) and is
expected to climb to 19.3 million per year in 2025 (WHO
2011; ICRC 2012). The estimated cancer-related deaths
was 8.2 million in 2012 (ICRC 2012). The majority of all
cancers (56.8%) and cancer deaths (64.9%) in 2012 oc-
curred in less developed countries (ICRC 2012). When
there is local and metastatic spread of cancer, complica-
tions arise and pain is an inevitable outcome. Over the
years, the use of opioids has been the mainstay for treating
cancer pain (Hanks 1991).
The WHO recommended the concept of ‘a three-
step analgesic ladder’ in the treatment of cancer pain* Correspondence: cho3699@gmail.com
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in any medium, provided the original work is p(Levy 1996; WHO 1996). In step III of the analgesic lad-
der, morphine is the drug of choice for the management
of moderate to severe cancer pain (WHO 1996, 2009;
Quigley 2004). However, published studies had reported
that adequate analgesia with morphine was not achieved
in 10-30% of patients with cancer pain (Cherny et al.
2001; Wiffen et al. 2003; Quigley 2004; WHO 2009).
Along this line, alternatives to morphine which are
novel formulations of existing drugs (Hanks et al. 2001)
are available.
Buprenorphine, synthesized in the late 1960s was used
as a parenteral analgesic since 1978. Buprenorphine is
also available in the forms of sublingual (SL) tablets or
transdermal (TD) patches. It is a partial agonist at μ-
opioid receptors (MOR) (Yaksh and Wallace 2011), an
antagonist at kappa opioid receptors (KOR) (Yaksh and
Wallace 2011) and a partial agonist at opiate receptor-
like receptor (ORL-1) (Lutfy and Cowan 2004).n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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view showed that maintenance dose was less effective
with buprenorphine than methadone. (Mattick et al.
2008). Thus, it is of immense value to provide evidence
of the efficacy and safety of opioid analgesics for cancer
pain.
Reviews which addressed the efficacy of TD buprenor-
phine are available for chronic treatment of moderate to
severe pain (Deandrea et al. 2009; Tassinari et al. 2011)
and for cancer pain (Wolff et al. 2012; Naing et al.
2013). All these reviews assessed TD buprenorphine, ex-
cluding other non-TD administration of buprenorphine.
A review covering buprenorphine delivered via any route
for treating cancer pain would be more informative and
valuable in comparison. Taken collectively, the objectives
of the present study were to synthesize available evi-
dence on the analgesic efficacy of buprenorphine in




We searched electronic databases of MEDLINE, EMBASE,
CINAHL and the Cochrane Library up to July 2013. We
also searched the reference sections of the selected studies
and relevant reviews for any additional studies which were
not found in the initial search. We followed the search
terms used in our earlier publication (Naing et al. 2013).
The search strategies were a combined search terms for
the cancer and for buprenorphine. The searched term for
cancer included; “cancer, human” [MeSH] OR “malig-
nancy” OR “cancer, gastrointestinal” OR “cancer, bladder”
Or “cancer, breast” OR “cancer, stomach” OR “cancer,
colon” OR “cancer, prostate” OR “cancer, lung”. Searched
term for buprenorphine included; “buprenorphine” OR
“bupre*”.
Selection criteria
We included studies following the PICOS criteria; (1)
(Participants, P): those patients with cancer, regardless
of age, gender, type of cancer and healthcare settings; (2)
(Intervention, I) studies where participants in one arm
should use buprenorphine, regardless of route of admin-
istration; (3) (Comparison, C) studies which compared
the efficacy of buprenorphine with placebo, other opioid
analgesic or no treatment; (4) (Outcome, O) the propor-
tion of participants with the changes in intensity of can-
cer pain; and (5) (Study design, S): RCT in which
efficacy of buprenorphine preparations was assessed in
cancer patients.
Studies were excluded if they (i) were not RCTs, (ii)
did not assess pain as an outcome measure, (iv) were
carried out with fewer than 10 participants, (v) were
conducted with those who had pain with the absence ofcancer, (vi) were assessed where pain was related to
treatments (chemotherapy-induced neuropathic pain), or
(vii) were assessed with pain due to surgical procedures.
We also excluded studies on pharmacodynamics, phar-
macoeconomics, case reports and conferences reports.
Data extraction and risk of bias assessment
Two authors independently screened all citations and re-
trieved article(s) which were considered eligible for the
present review. The two authors independently extracted
data from the studies, using a piloted-data extraction form.
The following information was collected: study design,
sample size, participant characteristics, cancer status,
drugs and their dosing, duration of study and follow-up,
analgesic outcome measures, adverse events (AE’s) and
serious adverse events (SAE’s). We resolved any discrep-
ancy by discussion.
The two authors independently determined quality of
studies following the Cochrane risk of bias tool (Higgins
and Green 2011). The domains assessed were ‘random
sequences generation’, ‘allocation concealment’, ‘blinding
of participants and/or outcome assessment’ and they were
categorized as ‘low’ ‘high’ or ‘unclear’ risk of bias. Discrep-
ancies were resolved by consensus.
Statistical analysis
The primary outcomes of interest were ‘patient-reported
pain intensity’ and ‘pain relief ’ as measured by validated
scales such as verbal rating scales (VRS), visual-analogue
scales (VAS) and numerical rating scales (NRS). The sec-
ondary outcomes were incidence of buprenorphine-
related AE and SAE. We performed meta-analysis when
2 or more individual studies were suitable for pooling on
the basis of similarity. Dichotomous data were compared
using a relative risk (RR) and respective 95% confidence
interval (CI). We assessed statistical heterogeneity by I2
test; a value of I2 > 50% indicated substantial heterogen-
eity (Higgins and Green 2011). If there was substantial
heterogeneity among studies, we used the DerSimonian
and Laird random effect model when pooling data and
calculated summary RR and respective 95% CI. We also
reported the number-needed-to-treat (NNT) for signifi-
cantly different outcome. In order to test the robustness of
our results, we reanalyzed the effect estimates by excluding
individual studies from the meta-analysis (leave-one-out
sensitivity analysis). For an assessment of reporting bias,
we visually inspected the funnel plots. However, asymmet-
rical funnel plot may be considered due to other possible
bias such as difference in methodological quality among
studies (Higgins and Green 2011).
Data entry and analyses were done using RevMan Version
5 · 2 (The Nordic Cochrane Centre, Copenhagen). The
present review has been reported according to the preferred
reporting items for systematic reviews and meta-analyses
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col of this study is available (Naing et al. 2012).
Results
Figure 1 shows the summary of study selection process.
The literature search yielded 984 citations. Thirty six that
examined the efficacy of buprenorphine were potentially
relevant. A total of 16 studies (n = 1329) with four differ-
ent routes of administration (subcutaneous, SL, IM, TD)
were identified for the present review.
Characteristics of the included studies (Table 1)
Buprenorphine was applied TD in 8 studies, SL in 5
studies, IM in 2 studies and subcutaneous infusion (SC)
in one study. Both SL and IM routes were assessed in
one study (Dini et al. 1986). Both SC and IM routes were
assessed in one study (Noda et al. 1989). The majority of
the included studies (10/16: 62.5%) were with the sampleFigure 1 Study flow diagram.size less than 100 (ranges: 17–189). The comparator
drugs included placebo, pentazocine, morphine, TD fen-
tanyl and tramadol. Six studies were cross-over studies
with each patient serving as his/her own control, while 9
studies were parallel-group comparisons and one study
was within dose comparison. In accordance with the def-
inition of enriched described elsewhere (Straube et al.
2008), three studies were completely enriched (Bohme
and Likar 2003; Sorge and Sittl 2004; Poulain et al. 2008)
and one study was partially enriched (Aurilio et al.
2009). Reported outcomes in the i analysed studies in-
cluded a number of validated scales subjectively used for
pain intensity and/or pain relief (e.g. VAS, VRS, NRS,
questionnaires), requirement for rescue drugs, duration
of pain-free sleep and presence of AE’s and SAE’s. As
several different pain scoring systems were employed in
these studies, a comprehensive comparison could not be
made between all of them.








Mean age Route Comparator drugs Outcome
measurement
Remarks




Multicenter 151 (70:81) 60.6 (± 12.2) TD Placebo VRS, responder Complete enriched;
mixed with non-cancer
& cancer patients
Bono 1997 Italy Cross-over 60 (44:16) 61.4 (40-84) SL Oral tramadol VAS, KSI Non-English
Brema 1996 Italy Multicenter 131 (86:45) SL Oral tramadol VAS, KSI Non-English
De Conno 1987 Italy Cross-over 91 SL Oral pentazocine Pain relief, KSI Non-English
Dini 1986 Italy Single centre 42 (21;21) 0.3 mg SL & IM Oral pentazocine
& IM pentazocine
Pain reduction. PI Non-English
Kjaer 1982 Denmark Single centre 27 (13:14) 60 (41-71) IM IM morphine Pain reduction
Likar 2007 Austria Cross-over,
open label
17 61.6 (±11.5) TD TD buprenorphine
(4day vs 3 day regimen)
PI A subset of cancer
patients
Noda 1989 Japan Single centre 30 range: 25-72 SC & IM Placebo VAS
Pace 2007 Italy Open label 52 (27:15) 55 (± 2.6) TD Morphine PI Non-enriched







157 (71:86) 58.7 (±11.8) TD Placebo Pain relief, PI,
satisfaction





137 56 (±12.1) TD Placebo VRS, Complete enriched;
33% cancer patients
Taguchi 1982 Japan Cross-over 31 IM IM pentazocine PI Non- English
Ventafridda 1983 Italy Cross-over 60 (42:18) >18 SL Oral pentazocine VAS, PI VAS
Wirz 2009 Germany Multidrug 174 (98:76) 65.3 (±10.7) TD Oral hydromorphone PI, rescue Prospective
non-English: non-English language publication; ITT: intention-to-treat analysis; IM : intramuscular injection; KSI: NRS: PPI: PRI: Pain rating index; SC: subcutaneous
administration; SL: sublingual administration; TD: transdermal administration; rescue: requirement of rescue drug; VAS: VRS, : Mean age: Mean age in year
(±SD or range); cross-over: cross-over studies; multidrug: more than 1 comparator drug; Responders; a composite scale; PI: pain intensity.
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Overall, many studies had high risk of bias (Table 2).
Blinding of participants or outcome assessment was
done in 4 studies (Bohme and Likar 2003; Sorge and
Sittl 2004; Poulain et al. 2008; Aurilio et al. 2009). Most
of the studies (87.5%) had short intervention duration
(≤ 15 days).Efficacy estimation (Table 3)TD buprenorphine
Eight studies examined the use of TD buprenorphine for
cancer pain (Bohme and Likar 2003; Sittl et al. 2003;
Sorge and Sittl 2004; Likar et al. 2007; Pace et al. 2007;
Poulain et al. 2008; Aurilio et al. 2009; Wirz et al. 2009).
In 2 studies (n = 241) (Pace et al. 2007; Poulain et al.
2008), ‘global impression of change’ was significantly differ-
ent between TD buprenorphine and a combined compara-
tor (placebo and morphine) (RR:1.35, 95% CI:1.14-1.59,
I2; 42%); the NNT was 4.9 (3.1-10.9).Two studies (n = 288) (Bohme and Likar 2003; Sittl
et al. 2003) assessed assessed the number of responding
patients. Responders were defined as those whose pain
relief was at least satisfactory at all determination points
(excluding the final examination) and who took a mean
of 0.2 mg per day or less of SL buprenorphine on day 7–12
(Bohme and Likar 2003); the efficacy was more pro-
nounced in TD buprenorphine 52.5 μg/h (RR:1.83, 95%
CI:1.12-2.99, I2; 64%) and 70 μg/h (RR:1.87, 95%
CI:1.17-3.0, I2; 0%). In 2 studies (Bohme and Likar
2003; Sorge and Sittl 2004), ‘the duration of pain free
sleep’ (> 6 hrs) was significantly different between TD
buprenorphine and placebo (RR: 3.02, 95% CI: 1.12-8.17;
I2: 0%). Two studies (n = 331) (Sittl et al. 2003; Sorge and
Sittl 2004) reported a comparable requirement for rescue
SL buprenorphine between TD buprenorphine and pla-
cebo (RR: 1.25, 95% CI: 0.71-2.18; I2:40%).
SL buprenorphine
Five studies examined SL buprenorphine in treating can-
cer pain (Dini et al. 1986; Brema et al. 1996; De Conno












Aurilio 2009 Unclear High Unclear Unclear Unclear
Bohme 2003 Unclear Unclear Low Low Unclear
Bono 1997 Low Unclear Low Unclear Unclear
Brema 1996 Unclear Unclear Unclear Unclear Low
De Conno 1987 Unclear Unclear Unclear Unclear Unclear
Dini 1986 Unclear Unclear Low Unclear Unclear
Kjaer 1982 Unclear High Unclear Low Unclear
Likar 2007 Unclear Low High High Low
Noda 1989 Unclear Unclear Unclear Unclear High
Pace 2007 Low Unclear Unclear Unclear Unclear
Poulain 2008 Low Low Low Unclear Unclear
Sittl 2003 Unclear Unclear Unclear Unclear High
Sorge 2004 Low High High Unclear Unclear
Taguchi 1982 Unclear Unclear Low Unclear Unclear
Ventafridda 1983 Unclear Unclear Unclear Unclear Unclear
Wirz 2009 Low Unclear High High High
Low: low risk of bias; high: high risk of bias; Unclear: Unclear risk of bias.
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1997). There were insufficient data for pooled analysis.
In one study (n=21) (Dini et al. 1986), ‘any pain improve-
ment’ was not significantly different between SL bupre-
norphine and pentazocine or tramadol (RR:2.29, 95%
CI: 0.24-21.55).
IM buprenorphine
Three studies (Kjaer et al. 1982; Taguchi 1982; Dini et al.
1986) assessed the use of IM buprenorphine in patients
with cancer pain. Due to inconsistency in data reporting
and/or insufficient data, it was not possible to summarize
the estimates. In 2 studies (Taguchi 1982; Dini et al. 1986),
‘pain relief ’ was significantly better with IM buprenor-
phine 0.2 mg single dose (RR:3.7, 95% CI:1.72-7.93, I2: 0%)
or IM buprenorphine 0.3 mg single dose (RR:3.03, 95%
CI:1.4-6.54, I2: 0%) than in IM pentazocine group.
SC administration
One study (Noda et al. 1989) reported that the use of SC
buprenorphine at the rate of 4 g/kg/day for 48 hour in
cancer patients gave satisfactory pain relief without ser-
ious complication. However, as the findings were based
on uncontrolled series of only 30 patients, it should be
interpreted with caution.
Frequency of AE’s
Overall, AE’s were not consistently reported across stud-
ies. In 2 studies (n = 171) (Pace et al. 2007; Wirz et al.
2009), ‘incidence of nausea’ was significantly lower in TDbuprenorphine than in morphine (RR: 0.38, 95% CI: 0.2-
0.71, I2: 0%). In 2 studies (n = 294) (Sittl et al. 2003; Pace
et al. 2007), ‘skin reaction’ was comparable between TD
buprenorphine and hydromorphone (RR:1.42, 95% CI:
0.73-2.76, I2: 0%). Also, in combining 2 studies (n = 189)
(Sittl et al. 2003; Sorge and Sittl 2004), ‘incidence of CNS-
related events’ was comparable between TD buprenorphine
and comparator (i.e. placebo or hydromorphone) (RR:0.74,
95% CI:0.33-1.66, I2:0%).
Of the five studies with SL buprenorphine, 3 studies
reported AE’s. However, it was not consistently reported
in these studies. In 2 studies (n = 141) (Dini et al. 1986;
De Conno et al. 1987), ‘incidence of vomiting’ was com-
parable between SL buprenorphine and pentazocine (RR:
1.28, 95% CI: 0.6-2.72, I2: 0%). In 3 studies (n = 261)
(Dini et al. 1986; De Conno et al. 1987; Bono and Cuffari
1997), ‘incidence of CNS-related events’ was comparable
between SL buprenorphine and tramadol or pentazocine
(RR: 0.89, 95% CI: 0.16-4.95, I2: 64%).
AE’s were not consistently reported in 3 studies with the
use of IM buprenorphine.
A subset of study (n = 21) reported that none (0/11)
was intolerable with AE’s in IM buprenorphine, but 20%
(2/10) in IM pentazocine (Dini et al. 1986).
In a study (n = 30), AE’s were fewer in SC buprenor-
phine than in placebo (Noda et al. 1989). In 2 studies
(n = 288) (Bohme and Likar 2003; Sorge and Sittl 2004),
‘incidence of withdrawals’ was comparable between TD
buprenorphine and placebo (RR: 1.26, 95% CI:0.48-3.31).
In 2 studies (n = 201) (Brema et al. 1996; Bono and Cuffari
Table 3 Comparative efficacy of buprenorphine
Description Number of studies
(study included)








2 (Poulain et al. 2008;
Pace et al. 2007)




Responders 35.5 μg/h 2 (Bohme and Likar 2003;
Sittl et al. 2003)
27/76 17/75 1.58 (0.94-2.66);
I2:39%
Responders 52.5 μg/h 2 (Bohme and Likar 2003;
Sittl et al. 2003)




Responders 70 μg/h 2 (Bohme and Likar 2003;
Sittl et al. 2003)






2 (Sorge and Sittl 2004:
Sittl et al. 2003)





2 (Sorge and Sittl 2004:
Sittl et al. 2003)






2 (Sorge and Sittl 2004:
Wirz et al. 2009)
45/151 70/160 1.03 (0.8-1.32);
I2: 69%
Nausea 2 (Pace et al. 2007;
Wirz et al. 2009)




Constipation 2 (Aurilio et al. 2009;
Wirz et al. 2009)
32/77 33/71 0.89 (0.55-1.17);
I2: 0%
TD fentanyl
Constipation 2 (Pace et al. 2007;
Wirz et al. 2009)
30/87 36/84 0.89 (0.55-1.17);
I2: 81%
Morphine
CNS- related AEs 2 ((Pace et al. 2007;
Sittl et al. 2003)
12/116 9/73 0.74 (0.33-1.66);
I2: 0%
Skin related AEs 2 (Sorge and Sittl 2004:
Sittl et al. 2003)
38/209 9/85 1.42 (0.73-2.76);
I2: 16%
SAEs Deaths 2 (Bohme and Likar 2003;
Sittl et al. 2003)




(with 0.3 mg dose)
2 (Dini et al. 1986;
Taguchi 1982)
22/42 6/34 3.03 (1.4-6.54);
I2: 0%
Any pain improvement
(with 0.2 mg dose)
2 (Dini et al. 1986;
Taguchi 1982)
23/35 6/34 3.7 (1.72-7.93);
I2: 0%
AE’s: adverse events, SAE’s: Serious adverse events; CNS: central nervous system; IM : intramuscular injection; NNT: number-needed-to treat; RR: relative risk;
SL: sublingual administration; TD: transdermal administration.
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tween SL buprenorphine and oral tramadol (RR: 4.26, 95%
CI:0.25-73.96). In 2 studies (n = 230) (Bohme and Likar
2003; Sittl et al. 2003), ‘incidence of deaths’ was compar-
able between TD buprenorphine and placebo (RR: 1.48,
95% CI: 0.23-9.66).
Other manifestations
When patients were switched from one opioid to another
(i.e. TD buprenorphine and TD fentanyl), the effects of an-
algesia and respiratory depressant of the second opioid (TD
fentanyl in this review) was pronounced in some patients
due to ‘incomplete cross tolerance’ (Levy 1996). AE’s in pa-
tients in cross-over studies (Likar et al. 2007; Aurilio et al.
2009) were likely to be related to this important effect.Discussion
The present review focused on the analgesic efficacy and
tolerability of buprenorphine given by four different ad-
ministration routes, SC, SL, IM or TD. We were unable
to synthesize the estimations in the non-TD route of
buprenorphine. This was due to the (1) small number of
studies with small numbers of participants included; (2)
different SL retention times (3) different eventual dispos-
ition of the SL tablet (swallowed or expectorated) (Robbie
1979; Reisfield and Wilson 2007); (4) different total doses
of IM administrations or (5) different outcome measures.
Overall, limitations in volume or surface area of SL space
could cause drugs given via SL route to possibilities of
ulceration, while the TD route is a non-invasive alterna-
tive to the oral route, particularly for stable pain states
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studies have provided some indication of pain improve-
ment over short-term studies (≼15 days follow- up).
Moreover, AE’s such as nausea and the requirement of
prophylactic antiemetic were significantly lower in the
TD buprenorphine group. Published non-Cochrane re-
views have assessed TD buprenorphine in particular for
non-cancer pain (Deandrea et al. 2009; Rossitto et al.
2009). In these reviews, incidences of nausea and treat-
ment termination were significantly fewer in TD bupre-
norphine group than in TD fentanyl group. This is
comparable to our findings, although variations in the
number of studies and inclusion criteria do exist. Bupre-
norphine has the theoretical and potential advantage of
being an opioid partial agonist with low abuse potential
(Robbie 1979; Bohme and Likar 2003) and approximate
equal bioavailability by the SL and TD routes (Skaer
2006).
Of note is the marked inequality between the groups
of TD buprenorphine and placebo in a completely
enriched study (Sorge and Sittl 2004). For instance, pa-
tients in the placebo group had a better starting con-
dition and run-in phase. Also, more patients in the
placebo group had received radiotherapy shortly before
the onset of the study, contributing to their better pain
status. Buprenorphine, when delivered via the TD route
passively diffused into the systemic circulation (Bohme
and Likar 2003; Sorge and Sittl 2004), providing a slower
increase in serum concentration and no peak-and-
trough effects as seen with the SL route (Yaksh and
Wallace 2011; Al-Tawil et al. 2013). This is the reason
why in many cases SL buprenorphine is used as rescue
analgesic. As a matter of fact, TD buprenorphine is non-
invasive and a suitable choice for cancer pain relief even
in the presence of renal disease. It also has a beneficial
ceiling effect for respiratory depression. A recent phar-
macokinetic study has reported that the systemic ex-
posure to TD buprenorphine was sufficiently similar
between elderly (> 75 years) and younger (50–60 years)
participants (Fudala et al. 2003). However, due to the
heterogeneity of the published data and small sample
sizes, the current meta-analysis has thus some limita-
tions to provide sufficient evidence.
We acknowledge some limitations of this review. If
not all, most of the included studies had small sample
sizes (< 100 in each arm), therefore it has inadequate
power to detect significant difference. Due to the small
number of participants in a small number of studies, the
results of this review provide insufficient evidence to
position adequately the use of buprenorphine in treat-
ment of cancer pain. One third of studies with low risk
of bias administered the TD buprenorphine (compared
with placebo or other opioid analgesics) when pain levels
were moderate or severe, ensuring that the studies weresensitive to detect pain-related outcomes. The preferred
outcome measure ‘50% pain relief ’, was not reported in
any included studies. Moreover, chronic pain studies
(cancer pain in this case) of short duration (≲ 6 weeks)
have manifested greater treatment effects than those of
longer duration (≳ 8 weeks). Fourteen studies (87.5%)
were conducted over short intervention duration (≲ 15 days).
Furthermore, severity of pain in cancer patients could be
related to the result of a progression of the underlying dis-
eases. Many cancer patients could have secondary metas-
tases at the time of the studies (Likar et al. 2007). It was
documented that marked escalation of opioid doses may
be required (i.e. by 100 times or more) for those patients
with solid tumours with metastases to the spine or central
nervous system (Zhang et al. 2003). However, inadequate
data precluded us from doing stratified analysis according
to the tumour types. Furthermore, data were based on
mixed groups (cancer pain and non-cancer pain) in some
studies and we could not analyse cancer patients in such
studies separately. The effect of such a selection bias was
considered with caution. Hence, accuracy of effect estima-
tion in the present review remains a concern.
Conclusions
In the treatment of cancer pain, low level of evidence
exists for the benefit of buprenorphine particularly with
TD administration. Large multicenter RCTs that compare
TD buprenorphine with standard analgesic treatment is
needed to position TD buprenorphine in the therapeutic
armamentarium of cancer pain treatment. As the invasive
route is relatively unfavourable for use in the treatment of
patients with cancer pain, there is no justification for fur-
ther research with IM buprenorphine.
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